Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: We assess the performance of ultrasound (US) and hepatobiliary scintigraphy (HIDA) as confirmatory studies in acute cholecystitis (AC) and demonstrate our current imaging protocol's impact on outcomes.

Study Design: Between January 2013 to July 2014, 117 patients were admitted through the emergency room with a preliminary diagnosis of AC. Overall, 106/117 (91%) of the patients received US preadmission and 34/117 (29%) received a HIDA post admission. Primary end points included: 1) diagnostic test reliability for AC, and 2) outcome and quality measures (time to surgery, LOS, costs, etc.).

Results: Laparoscopic cholecystectomy was performed in 96/117 (82%) and open cholecystectomy in 21/117 (18%) of the patients. Overall, histopathologic features consistent with AC was present in 46/117 (39%). AC alone was present in 23/117 (20%), and AC superimposed on chronic cholecystitis was present in 23/117 (20%). For AC, US had a sensitivity and specificity of 26% and 80%, respectively. HIDA scan had a sensitivity and specificity of 87% and 79%, respectively. Time to surgery (TTS) was 4 vs 2.3 days in patients who received HIDA vs US alone (p = 0.001), and length of stay (LOS) was 6.7 vs 4.3 days, respectively (p = 0.001). Age >50 years, glucose >140 (mg/dl), and WBC count >10 (×10 /L) were statistically significant independent variables associated with AC.

Conclusion: HIDA scan is superior to US as a diagnostic study in the setting of AC. Our current protocol of delayed HIDA (post-admission) was associated with increased TTS, LOS, and overall costs. Early confirmation with HIDA in high risk patients may hasten treatment allocation and improve outcomes in the setting of AC.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijsu.2016.09.084DOI Listing

Publication Analysis

Top Keywords

hepatobiliary scintigraphy
8
acute cholecystitis
8
patients received
8
received hida
8
time surgery
8
los costs
8
23/117 20%
8
sensitivity specificity
8
hida scan
8
hida
7

Similar Publications

Objective: Phenobarbital is an inductor of microsomal hepatic enzyme and used as choleretic for cholestatic liver disease to enhance bile flow. It is also used as a premedication for hepatobiliary scintigraphy (HIDA) scan to improve diagnostic accuracy for an obstructive liver disease. We reviewed the available literature on the use of Phenobarbital for treatment of cholestasis and its utility as a premedication for HIDA scan.

View Article and Find Full Text PDF

Pancreatic cancer is aggressive with high recurrence rates, necessitating accurate prediction models for effective treatment planning, particularly for neoadjuvant chemotherapy or upfront surgery. This study explores the use of variational autoencoder (VAE)-generated synthetic data to predict early tumor recurrence (within six months) in pancreatic cancer patients who underwent upfront surgery. Preoperative data of 158 patients between January 2021 and December 2022 was analyzed, and machine learning models-including Logistic Regression, Random Forest (RF), Gradient Boosting Machine (GBM), and Deep Neural Networks (DNN)-were trained on both original and synthetic datasets.

View Article and Find Full Text PDF

Introduction: Biliary atresia (BA) is a progressive cholestatic disease in neonates and infants, and early diagnosis and treatment significantly impact prognosis. Definitive diagnosis is based on cholangiogram findings, classifying BA into three main types. Among its variants, type I-b1-β-where the common bile duct is blocked, the distal duct is fibrous, and the tiny intrahepatic ducts are underdeveloped-is particularly rare.

View Article and Find Full Text PDF

: F-PSMA-1007 is one of the more widely used radioligands in prostate cancer imaging with PET/CT. Its major advantage lies in the low urinary tracer activity due to primarily hepatobiliary clearance, but unexpectedly high tracer accumulation in the bladder can occur, potentially hindering assessment of lesions near the prostate bed. This study assesses the impact of furosemide on F-PSMA-1007 tracer accumulation in the bladder.

View Article and Find Full Text PDF

C-labeling of 20(S)-protopanaxadiol, an aglycon of ginsenoside, based on the use of Pd(0)-mediated rapid C-[C]methylation of boronic precursors.

Bioorg Med Chem Lett

December 2025

Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, 7-430 Morioka-cho, Obu-shi, Aichi 474-8511, Japan. Electronic address:

Ginsenosides, the pharmacologically active components of Panax ginseng, are widely used in herbal medicine and reportedly exert diverse biological effects, including anticancer, anti-inflammatory, and neuroprotective activities. However, their pharmacological mechanisms remain poorly understood, owing to the lack of chemical probes suitable for in vivo analyses. Herein, we report the development of a C radiolabeling of 20(S)-protopanaxadiol (PPD), a major aglycone-type active ginsenoside metabolite, for positron emission tomography (PET) imaging.

View Article and Find Full Text PDF